Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.210 Biomarker disease RGD In colon cancer, apobec-1 protein levels decreased by 90% in the cancer tissue as compared to normal tissue, suggesting an inhibitory effect of the 5'UTR on apobec-1 translation. 12020819 2002
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.210 AlteredExpression disease BEFREE Apobec-1 mRNA was detectable in normal and colon cancer tissue, metastatic nodules, and certain colon cancer-derived cell lines. 9797364 1998
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.200 Biomarker disease RGD Effects of a thyromimetic on apolipoprotein B-100 in rats. 11116209 2000
CUI: C0020476
Disease: Hyperlipoproteinemias
Hyperlipoproteinemias 		0.200 Biomarker disease RGD Effects of a thyromimetic on apolipoprotein B-100 in rats. 11116209 2000
CUI: C0028754
Disease: Obesity
Obesity 		0.200 Biomarker disease RGD In contrast, the hepatic mRNA encoding APOBEC-1, the catalytic subunit of the RNA editing activity, demonstrated an increased abundance of 1.8-fold in obese Zucker rats versus lean controls. 8781289 1996
CUI: C1333419
Disease: Liver and Intrahepatic Bile Duct Epithelial Neoplasm
Liver and Intrahepatic Bile Duct Epithelial Neoplasm 		0.200 Biomarker disease RGD Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. 9633945 1998
CUI: C1333976
Disease: Liver and Intrahepatic Bile Duct Neoplasm
Liver and Intrahepatic Bile Duct Neoplasm 		0.200 Biomarker disease RGD Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. 9633945 1998
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.030 Biomarker disease BEFREE RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis. 9633945 1998
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.030 Biomarker disease BEFREE Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice. 20976059 2010
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.030 Biomarker disease BEFREE Here, we placed hypercholesterolemic Ldlr-/-Apobec1-/- mice on a high-fat diet and treated them with either 25 mg/kg/day of clopidogrel (CLO) or 180 mg/kg/day of TIC for 16 weeks and evaluated the extent of atherosclerosis. 31242230 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.030 Biomarker disease BEFREE Here, we placed hypercholesterolemic Ldlr-/-Apobec1-/- mice on a high-fat diet and treated them with either 25 mg/kg/day of clopidogrel (CLO) or 180 mg/kg/day of TIC for 16 weeks and evaluated the extent of atherosclerosis. 31242230 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.030 Biomarker disease BEFREE Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice. 20976059 2010
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.030 Biomarker disease BEFREE RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis. 9633945 1998
CUI: C0014544
Disease: Epilepsy
Epilepsy 		0.020 Biomarker disease BEFREE Corrigendum: A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy. 31105523 2019
CUI: C0014544
Disease: Epilepsy
Epilepsy 		0.020 Biomarker disease BEFREE A Novel RNA Editing Sensor Tool and a Specific Agonist Determine Neuronal Protein Expression of RNA-Edited Glycine Receptors and Identify a Genomic APOBEC1 Dimorphism as a New Genetic Risk Factor of Epilepsy. 29375302 2017
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.020 AlteredExpression disease BEFREE C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. 11727199 2002
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.020 AlteredExpression disease LHGDN Taken together, the data support the hypothesis that C-->U RNA editing of the NF1 transcript occurs both in a subset of PNSTs and in an alternatively spliced form containing a downstream exon, presumably an optimal configuration for enzymatic deamination by apobec-1. 11727199 2002
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.020 Biomarker disease BEFREE Overexpression of APOBEC-1 in transgenic animals caused liver dysplasia and APOBEC-1 has been identified in neurofibromatosis type 1 tumours, suggesting that RNA editing may be another mechanism for tumourigenesis. 11072063 2000
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.020 AlteredExpression disease BEFREE However, high-level expression of APOBEC-1 in transgenic mouse and rabbit livers causes liver dysplasia and hepatocellular carcinoma. 9633945 1998
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.020 AlteredExpression disease BEFREE The transgene expression of the catalytic subunit APOBEC-1 of the apo B mRNA editing enzyme-complex can cause hepatocellular carcinoma in mice and rabbits. 10597235 1999
CUI: C0002793
Disease: Anaplasia
Anaplasia 		0.010 Biomarker disease BEFREE Apobec1 Promotes Neurotoxicity-Induced Dedifferentiation of Müller Glial Cells. 28150227 2017
CUI: C0004763
Disease: Barrett Esophagus
Barrett Esophagus 		0.010 AlteredExpression disease BEFREE APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma. 25085003 2014
CUI: C0007785
Disease: Cerebral Infarction
Cerebral Infarction 		0.010 AlteredExpression disease BEFREE Apobec-1 could upregulate COX-2 expression in neurogenic cells by stabilizing COX-2 mRNA, and might aggravate injury of oxygen-glucose deprivation in neurogenic cells as well as in rats with cerebral ischemia. 23609497 2013
CUI: C0008350
Disease: Cholelithiasis
Cholelithiasis 		0.010 Biomarker disease BEFREE To investigate APOBEC1 and PPARG as candidate genes for common symptomatic gallstone disease in humans. 17696929 2007